Sterols are essential biological molecules in the majority of life forms. Sterol reductases 1 including D 14 -sterol reductase (C14SR, also known as TM7SF2), 7-dehydrocholesterol reductase (DHCR7) and 24dehydrocholesterol reductase (DHCR24) reduce specific carboncarbon double bonds of the sterol moiety using a reducing cofactor during sterol biosynthesis. Lamin B receptor 2 (LBR), an integral inner nuclear membrane protein, also contains a functional C14SR domain. Here we report the crystal structure of a D 14 -sterol reductase (MaSR1) from the methanotrophic bacterium Methylomicrobium alcaliphilum 20Z (a homologue of human C14SR, LBR and DHCR7) with the cofactor NADPH. The enzyme contains ten transmembrane segments (TM1-10). Its catalytic domain comprises the carboxy-terminal half (containing TM6-10) and envelops two interconnected pockets, one of which faces the cytoplasm and houses NADPH, while the other one is accessible from the lipid bilayer. Comparison with a soluble steroid 5b-reductase structure 3 suggests that the reducing end of NADPH meets the sterol substrate at the juncture of the two pockets. A sterol reductase activity assay proves that MaSR1 can reduce the double bond of a cholesterol biosynthetic intermediate, demonstrating functional conservation to human C14SR. Therefore, our structure as a prototype of integral membrane sterol reductases provides molecular insight into mutations in DHCR7 and LBR for inborn human diseases.
Sterols, amphipathic molecules, are widespread in animals, plants, fungi and some prokaryotes and a large variety exist 4 , including ergosterol, hopanoids, phytosterol and cholesterol. The most abundant sterol in animals is cholesterol, which not only has a vital role in the maintenance of membrane strength and permeability, but also serves as a precursor for the biosynthesis of steroid hormones 5, 6 . Endogenous biosynthesis is the major source of sterols, and the biosynthetic pathway from water-soluble small metabolites via intermediates of increasing complexity up to water-insoluble sterols encompasses numerous distinct enzymes 1,7 , many of which contain multiple transmembrane segments. To date, no structure of the integral membrane enzymes involving sterol biosynthesis has been determined. Sterol reductases 1 , integral membrane enzymes including C14SR, DHCR7 and DHCR24, can reduce specific carbon-carbon double bonds of the sterol moiety using a reducing cofactor at distinct steps in sterol and cholesterol biosynthesis (Extended Data Fig. 1 ).
Curiously, the multifunctional lamin B receptor 2 (LBR), located in the inner nuclear envelope membrane, also contains a domain in its Cterminal portion that is highly homologous to human sterol reductase 8 (Extended Data Fig. 2 ). Indeed, complementary DNA of human LBR complements reductase gene (ERG24) deletion in yeast, supporting the idea that LBR can substitute for sterol reductase activity 9 . Mutations in LBR and DHCR7 lead to various human genetic diseases 1 (Pelger-Huët anomaly 10 (PHA) and Greenberg skeletal dysplasia 11 (also known as hydrops-ectopic calcification-moth-eaten skeletal dysplasia, HEM) related to LBR; and Smith-Lemli-Opitz syndrome 12, 13 (SLOS) related to DHCR7). However, structural knowledge of these important membrane-embedded enzymes is lacking, and therefore a mechanistic understanding cannot be developed.
To gain more insight into sterol reductases, we set out to determine the crystal structure of one of its family members. In screening for crystalforming representatives of integral membrane sterol reductases, we found a homologue from the methanotrophic bacterium Methylomicrobium alcaliphilum 20Z, MaSR1, which shares 38-45% sequence identity and 51-62% similarity to human C14SR, DHCR7 and the Cterminal portion of LBR (Extended Data Fig. 2 ). Methylomicrobium alcaliphilum 20Z is an aerobic methanotroph, the cell membrane of which contains significant levels of sterols and hopanoids 14 .
Expression of MaSR1 complements the deletion of the D 14 -sterol reductase gene (ERG24) in yeast, indicating that MaSR1 is a bona fide sterol reductase (Extended Data Fig. 3, lanes 1-3) . To test whether MaSR1 can function in human cholesterol biosynthesis, we performed the sterol reductase activity assay of MaSR1 after expression in human HEK293 cells and employed 5a-cholesta-8,14-dien-3b-ol (C27D 8, 14 ), a human cholesterol biosynthetic intermediate analogue [15] [16] [17] of 4,4-dimethylcholesta-8,14-dien-3b-ol (C29D 8, 14 , Extended Data Fig. 1 ), as the substrate (Fig. 1a ). This assay has been used for initial identification 15 and further investigation 16, 17 of mammalian sterol reductases. The catalytic efficiency of MaSR1 is about 75% of that of human C14SR (Fig. 1b, c ). We conclude that MaSR1 can function like human C14SR and specifically reduce the double bond of the approximate cholesterol biosynthetic intermediate.
We crystallized MaSR1 in space group P1 with NADPH. The diffraction of the crystal is anisotropic (Methods and Extended Data Fig. 4 ). The structure was determined by selenium-based single-wavelength anomalous dispersion and refined at 2.74 Å resolution (Extended Data Tables 1 and 2). Introduction of additional selenium anomalous scatterers by selective mutation and preparation of platinum derivatives confirmed that the atomic model was correct (Extended Data Fig. 5 and Extended Data Table 3 ).
Two MaSR1 molecules (rotated by 180u) pack into a crystallographic dimer that forms the asymmetric unit. The dimensions of the MaSR1 monomer are 50 3 45 3 58 Å . The enzyme contains ten transmembrane helices (TM1-10). On the basis of the 'positive inside rule' for membrane proteins 18 , we assigned the amino and carboxy termini to face the cytoplasm, consistent with the biochemically determined topology of the yeast homologue Erg24 (ref. 19 ). There are two short antiparallel b-sheet regions (b1-4) interspersed in the cytoplasm-exposed loops as well as two short a-helices, designated a1 and a2 ( Fig. 2a and Extended Data Fig. 2 ). Residues 1-23 and 162-176 (part of the loop between TM4 and TM5) are not visible in the electron density map and therefore presumed to be disordered. The binding pocket for NADPH was localized to the C-terminal domain (TM6-10) and a cavity with an unidentified ligand density facing the lipid bilayer is surrounded by TM7 and TM10 (Fig. 2b, c) .
Except for the nicotinamide-ribose moiety, the remainder of the NADPH molecule could be clearly identified (Extended Data Fig. 6a, b ). The nicotinamide ring is the hydrogen donor in the transient interaction with the substrate. In our structure, the absence of a sterol substrate probably fails to coordinate the nicotinamide ring and hence causes it to be disordered. By contrast, the other half of the NADPH molecule is well defined in the electron density and stabilized by a hydrogen bond from the centrally located Tyr 414 of a2 (Fig. 3a) . The remainder of the NADPH pocket is lined with residues from TM9 and TM10 as well as two residues from TM8 (Fig. 3a) . The NADPH pocket extends further around TM10 providing enough space to house the nicotinamide-ribose moiety of NADPH (Extended Data Fig. 6c ). We mutated several residues in the NADPH binding pocket of MaSR1 (Extended Data Fig. 2 ). These mutations led to the loss of catalytic activity, as judged by the human D 14 -sterol reductase activity assay ( Fig. 1d ) and by the Erg24 complementation assay in yeast (Extended Data Fig. 3, lanes 4, 6 and 7) .
The working principle of reductases is to bring the nicotinamide of NADPH into close proximity to the substrate, leading to carbon-carbon double bond reduction. Analogous to the catalytic pocket of soluble steroid 5b-reductase 3 (AKR1D1, Protein Data Bank (PDB) accession number 3COT), bound to progesterone (Fig. 3b ), the lipid-bilayerfacing cavity of MaSR1 is the likely candidate for the sterol binding pocket (Fig. 3c) . Notably, the sterol binding pockets of both enzymes contain a 'signature' motif forming triangular hydrogen bonds that coordinate the b3 hydroxyl of either sterol or steroid; for MaSR1, this signature motif includes Tyr 241 bonded to Asp 363 ( Fig. 3c ) and for steroid 5breductase, Tyr 58 bonded to Glu 120 (Fig. 3b ). The distance between Tyr 58 and Glu 120 (4.1 Å ) in steroid 5b-reductase is similar to that of Tyr 241 and Asp 363 (3.9 Å ) in MaSR1. The MaSR1 double mutant Y241F/ D363A loses sterol reductase function in the human D 14 -sterol reductase activity assay ( Fig. 1d ) and the yeast Erg24 complementation assay (Extended Data Fig. 3, lane 5) . For the putative sterol binding pocket, extensive hydrophobic contacts between the highly conserved Trp 274 Figure 1 | D 14 -reductase activity of MaSR1. a, Reaction catalysed by transfected human C14SR or MaSR1 in which 5a-cholesta-8,14-dien-3b-ol (C27D 8, 14 ) is converted to 5a-cholesta-8-en-3b-ol (C27D 8 ). b, The average catalytic efficiency in two different experiments (calculated as the integrated gas chromatography-mass spectrometry (GC-MS) chromatogram peak area ratio C27D 8 /(C27D 8,14 1 C27D 8 )) of untransfected HEK293 cells and cells transfected with MaSR1, Flag-MaSR1 and human C14SR is 3.6%, 29.7%, 28.9% and 38.4%, respectively. The thin black lines show the spread between the two individual measurements c, GC-MS chromatograms of D 14 -sterol reductase assay. Peak 1, mass to charge ratio (m/z) 372, 5a-cholestane (an internal standard); peak 2, m/z 458, endogenous cholesterol; peak 3, m/z 456, C27D 8, 14 ; peak 4, m/z 458, C27D 8 . The reduced products (peak 4) were detected in MaSR1, Flag-MaSR1 and C14SR but little in untransfected cells. d, The catalytic efficiency of Flag-MaSR1 mutants. All mutants expressed by anti-Flag western blot (WB) detection. The plotted values in the grey bars are the average of two different experiments. The thin black lines show the spread between the measurements.
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and Tyr 387 residues enforce the interaction of TM7 and TM10 (Extended Data Fig. 6d ). Notably, in each monomer of the crystallographic dimer there is the extra electron density of an unidentified molecule in front of the cavity (Figs 2b and 3c ). Although the molecular identity of this density could not be unambiguously determined (maybe an endogenous molecule from Escherichia coli or the detergent used for purification), it may represent a substrate for the putative sterol binding pocket. We modelled that two binding pockets bring the reducing end of NADPH into close proximity to the sterol (steroid) carboncarbon double bond to be reduced (Fig. 3d ), similar to the aldo-keto reductase (AKR) family of enzymes involved in human steroidgenesis 20 (for example, AKR1C3 and AKR1C2).
Owing to the high sequence homology with human LBR and human DHCR7, we generated structural models based on MaSR1 to highlight disease-related mutations (Fig. 4) . The PHA/HEM-related mutations of LBR and the SLOS-related mutations of DHCR7 could be almost entirely mapped to the sterol reductase catalytic domain affecting the cofactor binding or sterol entry/binding sites. The similarities in pathogenesis between PHA/HEM and SLOS could therefore arise from a defect in sterol reduction.
Intriguingly, substrate recognition for sterol reductases is not very specific. MaSR1 could reduce the double bond of both C27D 8, 14 (Fig. 1b ) and of the yeast sterol substrate ergosta-8,14-dien-ol (Extended Data Fig. 3 ). This is consistent with previous observations for LBR: it can reduce C27D 8,14 (ref. 16) ; complement C14SR function in C14SR 2/2 (also known as Tm7sf2 2/2 ) mice 21 ; and also reduce different yeast sterol substrates 9 . Finally, our structure also provides insight into the function of LBR. A DALI search for structural homologues of MaSR1 shows 
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no similar entry for the entire MaSR1 structure. However, it identified the membrane-embedded isoprenylcysteine carboxyl methyltransferase 22 (ICMT, PDB accession number 4A2N) as the closest entry for the TM6-10 segments of MaSR1 (Extended Data Fig. 7) . The function of ICMT, which recognizes and then carboxymethylates the farnesylated cysteine of its substrate, points towards a similar role of the C14SR domain of LBR, which may recognize the farnesylated cysteine of either prelamin A or lamin B as the ligand 23 .
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
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METHODS
Protein expression and purification. We expressed a homologue of eukaryotic sterol reductases from the methanotrophic bacterium Methylomicrobium alcaliphilum 20Z (MaSR1, NCBI GI number: 503913803). Its cDNA was cloned into pET-21b (Novagen) with an N-terminal 8-His tag and expressed in E. coli C43(DE3) (Lucigen). The transformed cells were grown to an optical density of 1.0 at OD 600 and induced with 0.2 mM isopropyl-b-D-thiogalactopyranoside (IPTG). Cells were disrupted using a French press with two passes at 15,000 p.s.i., in a buffer containing 25 mM Tris-Cl, pH 8.0, and 150 mM NaCl (buffer A). After low-speed centrifugation, the resulting supernatant was centrifuged at high speed to sediment a membrane fraction, which then was incubated in buffer A with 2% (w/v) N-dodecylb-D-maltopyranoside (DDM, Anatrace) for 1 h at 4 uC. The lysate was centrifuged again and the supernatant was loaded onto Ni 21 -NTA affinity column (Qiagen). After washing twice, the protein was eluted with 25 mM Tris-Cl, pH 8.0, 150 mM NaCl, 300 mM imidazole, and 0.1% DDM, and concentrated by centricon for subsequent gel filtration (Superdex-200, GE Healthcare) in buffer A with 0.4% (w/v) N-nonylb-D-glucopyranoside (b-NG, Anatrace). The peak fraction was collected for crystallization. All mutations were generated using two-step PCR. Selenomethionine (SeMet)-labelled protein was purified similarly with the exception that 1 mM Tris [2-carboxyethyl] phosphine (TCEP) was included during the purification process.
Crystallization. Before crystallization, the protein solution was incubated with 2 mM NADPH (Sigma-Aldrich). Crystals were grown at 20 uC by the hanging-drop vapourdiffusion method. The crystals appeared after 5 days in the well buffer containing 0.1 M Tris-Cl pH 7.0, 0.2 M NH 4 Ac, 30% (v/v) pentaerythritol ethoxylate (15/4 EO/OH). DDM was added into crystallization buffer at 1% (v/v) final concentration to improve diffraction. SeMet-labelled protein was crystallized in the same buffer supplemented with 6 mM dithiothreitol (DTT). Platinum derivatives were obtained by soaking native crystals for 12 h in mother liquor plus 10 mg ml 21 K 2 Pt(NO2) 4 . All crystals were directly flash-frozen in a cold nitrogen stream at 100 K. Data collection and structure determination. The data were collected at National Synchrotron Light Source (NSLS) beamline X29. All data sets were processed using HKL2000 (ref. 24 ). Owing to the anisotropic diffraction properties, the outlier reflections were rejected based on extreme-value Wilson statistics using the program XTRIAGE 25 in the PHENIX package 26 . The anomalous signal in the SeMet-derivative data was further magnified with the local-scaling algorithm using the program SOLVE 27 . Then, the selenium sites were determined using the program SHELXD 28 . The identified sites were refined and the initial phases were generated in the program PHASER 29 with the single-wavelength anomalous dispersion experimental phasing module. Twofold NCS averaging along with solvent flattening and histogram matching was performed using DM 30 . The initial model was built in COOT 31 manually. The structure was refined with phenix.refine 26 . Model validation was performed with MolProbity 32 . Introduction of additional selenium anomalous scatterers by selective mutation and preparation of platinum derivatives confirmed the correctness of the atomic model. The homology models of human LBR and human DHCR7 were generated by the program MODELLER 33 on the basis of the structure of MaSR1 in which the N-terminal regions (1-200 of LBR and 1-58 of DHCR7) were excluded because of low sequence conservation (Extended Data Fig. 2 ). All figures were generated using the program PyMOL (http://www.pymol.org/). Yeast reductase complementation assay. Wild-type and mutant MaSR1 and ScErg24 were subcloned into the URA3 shuttle vector pCM190 (Euroscarf, Germany). The plasmids were introduced in Erg24-deficient Saccharomyces cerevisiae strain Y11164 (Euroscarf) by electroporation. A single colony was picked from a URA 2 selective plate. For the yeast rescue assay, the yeast was grown on URA 2 plates either in the absence or the presence of sub-inhibitory concentrations of cycloheximide (20 ng ml 21 ) at 30 uC for 24 to 48 h. The results were confirmed by three independent experiments with different colonies. D 14 -reductase assay. The cDNA encoding human D 14 -sterol reductase (C14SR) was subcloned into pCMV-SPORT6 (Open Biosystems). Wild-type and mutant MaSR1 were subcloned into pEGFP-N1 (Clontech) without the EGFP tag. HEK293 cells were grown in a 5% CO 2 incubator at 37 uC in DMEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U ml 21 penicillin and 0.1 mg ml 21 streptomycin. Cells were cultured in 10-cm Petri dishes to 80% confluence and transfected with the plasmids, using Lipofectamine 2000 (Life Technologies). After 48 h, transfected cells were recovered and the washed cell pellet was resuspended in PBS containing complete protease inhibitor cocktail (Sigma-Aldrich). Cells were lysed by sonication three times for 10 s on ice. After low-speed centrifugation, the resulting supernatant was ultracentrifuged to sediment a membrane fraction. The isolated membrane fraction was resuspended in 10 mM KPO 4 /0.5 mM EDTA (pH 7.4) and frozen in aliquots for further analyses. Protein concentration was determined by Bradford method, using bovine serum albumin as a standard. Proteins of the membrane fraction were separated by SDS-PAGE, blotted on PVDF and probed with mouse monoclonal anti-Flag M2 (Sigma-Aldrich) and peroxidase-conjugated goat anti-mouse (Santa Cruz). The protein was detected using Super Signal West Pico Chemiluminescent Substrate (Pierce). D 14 -reductase activity was assayed in the membrane fractions obtained from transfected cells (0.25 mg protein per assay) using 5a-cholesta-8,14-dien-3b-ol (C27D 8, 14 ) as a substrate [15] [16] [17] . After the addition of 5a-cholestane (5 mg) as an internal standard, sterols were extracted with petroleum ether, desiccated under nitrogen stream and converted to trimethylsilyl derivatives using N,O-Bis (trimethylsilyl) trifluoroacetamide (BSTFA) and pyridine (1:1, v/v). Gas chromatography-mass spectrometry (GC-MS) analysis was performed in multiple ion detection mode using a Varian GC-MS 2000 apparatus with a Varian CP-Sil8 CB low bleed capillary column. The trimethylsilylation of sterol products yields a molecular mass increase of 72 Da. Sterol retention times were: 15.31 min, 5a-cholestane (m/z 372); 19.90 min, cholesterol (m/z 458); 20.16 min, 5a-cholesta-8,14-dien-3b-ol (C27D 8, 14 , m/z 456); 20.34 min, 5a-cholesta-8-en-3b-ol (C27D 8 , m/z 458). D 14 -reductase catalytic efficiency is calculated as the peak area ratio C27D 8 /(C27D 8,14 1 C27D 8 ). The C27D 8 sterol was undetectable at zero incubation time.
